A 35-year-old woman from rural Maharashtra attends the primary health centre for cervical cancer screening. Pap smear is performed and reported as ASC-US (Atypical Squamous Cells of Undetermined Significance). HPV testing is not available at the centre. What is the most appropriate next step in management?

## Management of ASC-US Cytology **Key Point:** ASC-US is the most common abnormal Pap smear result and carries a low risk of underlying cervical intraepithelial neoplasia (CIN). The management algorithm depends on HPV testing availability and resource setting. ### ASC-US Management Pathways | Finding | Resource-Rich Setting | Resource-Limited Setting | | --- | --- | --- | | ASC-US + HPV positive | Colposcopy | Colposcopy or repeat cytology | | ASC-US + HPV negative | Routine screening | Routine screening | | ASC-US + HPV unavailable | Repeat cytology at 12 months | Repeat cytology at 12 months | **High-Yield:** In settings where HPV testing is unavailable (common in rural India), the standard recommendation is **repeat Pap smear after 12 months**. This is cost-effective and has acceptable sensitivity for detecting significant pathology. **Clinical Pearl:** ASC-US has only a 5–10% risk of underlying CIN2/3. Immediate colposcopy would result in unnecessary procedures and healthcare burden in resource-limited settings. ### Why Repeat Cytology Works 1. Low absolute risk of malignancy in ASC-US 2. Allows time for transient HPV infections to clear 3. Cost-effective in low-resource settings 4. Reduces overtreatment and anxiety **Mnemonic:** **ASC-US = Avoid Colposcopy Unless HPV Positive** (or repeat cytology if HPV unavailable). [cite:WHO Guidelines on Cervical Cancer Screening, FIGO 2023]